We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Audentes Therapeutics appointed Edward R. Conner, M.D. as Senior Vice President and Chief Medical Officer and promoted Fulvio Mavilio, Ph.D. to Senior Vice President of Translational Science.
Audentes Therapeutics has commenced dosing of patients in ASPIRO, a Phase 1/2 clinical trial of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).